(Q40940702)

25 September 2017

Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine (English)

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1978.TB06929.X

6 April 2023

0 references

1 reference

B. Wode-Helgodt

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A358755

6 April 2023

S. Borg

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A358755

6 April 2023

B. Fyrö

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A358755

6 April 2023

G. Sedvall

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A358755

6 April 2023

language of work or name

English

0 references

publication date

1 August 1978

1 reference

full work available at URL

25 September 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1600-0447.1978.tb06929.x

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1978.TB06929.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0447.1978.tb06929.x/fullpdf

6 April 2023

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1978.TB06929.X

Acta Psychiatrica Scandinavica

6 April 2023

published in

1 reference

25 September 2017

58

1 reference

25 September 2017

2

1 reference

25 September 2017

149-173

1 reference

Levels of chlorpromazine and its active metabolites in rat brain and the relationship to central monoamine metabolism and prolactin secretion

25 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1978.TB06929.X

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1978.TB06929.X

Factors affecting chlorpromazine plasma levels in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1978.TB06929.X

Plasma levels of chlorpromazine and some of its relatively non-polar metabolites in psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1978.TB06929.X

Effect of chlorpromazine and some of its metabolites on the accumulation of homovanilic acid in brain of mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1978.TB06929.X

Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1978.TB06929.X

The relationship of plasma chlorpromazine to its 7-hydroxy and sulphoxide metabolites in a large population of chronic schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1978.TB06929.X

Effect of chlorpromazine and some of its metabolites on the dopamine-sensitive adenylate cyclase of rat brain striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1978.TB06929.X

Effects of mode of management on plasma chlorpromazine in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1978.TB06929.X

Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1978.TB06929.X

A mass fragmentographic method for the determination of chlorpromazine and two of its active metabolites in human plasma and CSF.

21 January 2018

2

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1978.TB06929.X

Indoleamine metabolites in the cerebrospinal fluid of depressed patients before and during treatment with nortriptyline

6 April 2023

4

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1978.TB06929.X

Tricyclic antidepressant overdose: incidence of symptoms

6 April 2023

7

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1978.TB06929.X

The treatment of acute schizophrenia without drugs: an investigation of some current assumptions

6 April 2023

10

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1978.TB06929.X

Chlorpromazine in chronic schizophrenia: behavioral dose-response relationships

6 April 2023

11

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1978.TB06929.X

6 April 2023

Persistent Dyskinesia

12

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1978.TB06929.X

Self-inhibiting action of nortriptylin's antidepressive effect at high plasma levels: a randomized double-blind study controlled by plasma concentrations in patients with endogenous depression

6 April 2023

26

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1978.TB06929.X

Effect of chlorpromazine and some of its metabolites on synthesis and turnover of catecholamines formed from 14C-tyrosine in mouse brain

6 April 2023

31

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1978.TB06929.X

Correlation between plasma chlorpromazine and its metabolites and clinical ratings in patients with acute relapse of schizophrenic and paranoid psychosis

6 April 2023

33

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1978.TB06929.X

The possible role of metabolites in therapeutic response to chlorpromazine treatment

6 April 2023

36

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1978.TB06929.X

Physiologic and clinical effects of chlorpromazine and their relationship to plasma level

6 April 2023

37

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1978.TB06929.X

A rating scale for extrapyramidal side effects

6 April 2023

40

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1978.TB06929.X

Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients

6 April 2023

45

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1978.TB06929.X

Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patients

6 April 2023

46

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1978.TB06929.X

6 April 2023

Identifiers

1 reference

25 September 2017

1 reference